Treatment of alcoholic polyneuropathy with vitamin B complex: A randomised controlled trial

被引:24
作者
Peters, T. J.
Kotowicz, J.
Nyka, W.
Kozubski, W.
Kuznetsov, V.
Vanderbist, F.
De Niet, S.
Marcereuil, D.
Coffiner, M.
机构
[1] Kings Coll London, Dept Clin Biochem, London SE5 9RS, England
[2] Wojskowy Inst Med, Klin Neurol & Poradnia, Dept Neurol, Warsaw, Poland
[3] Med Univ Gdansk, Dept Neurol Adults, Gdansk, Poland
[4] Univ Med Sci, Dept Neurol, Poznan, Poland
[5] Kiev Med Acad Postgrad Educ, Dept Psychiat, Kiev, Ukraine
[6] R&D Dept, Lab SMB, Brussels, Belgium
来源
ALCOHOL AND ALCOHOLISM | 2006年 / 41卷 / 06期
关键词
D O I
10.1093/alcalc/agl058
中图分类号
R194 [卫生标准、卫生检查、医药管理];
学科分类号
摘要
Aims: To evaluate the therapeutic efficacy and safety of BEFACT (R) Forte 'new formulation' and BEFACT (R) Forte 'old formulation' in the treatment of sensory symptoms of alcoholic polyneuropathy. Methods: A multi-centre, randomised, double-blind, placebo-controlled study was conducted on 325 patients with sensory symptoms and signs of alcoholic polyneuropathy. Patients were randomised to the 'old formulation' (i.e. vitamins B-1, B-2, B-6, and B-12), 'new formulation' [i.e. identical to the 'old formulation' with additional folic acid (vitamin B-9)], or placebo in a 1:1:1 ratio. One tablet of the study medication ('new formulation' or 'old formulation') or placebo was taken orally, three times a day, over a 12-week treatment period. Results: Therapeutic efficacy was assessed in 253 patients by measuring vibration perception threshold (biothesiometry), intensity of pain, sensory function, co-ordination, and reflex responses. Patients treated with the 'new formulation' or 'old formulation' showed significant improvement in the primary efficacy endpoint (vibration perception threshold at the big toe) and secondary efficacy endpoints in comparison to placebo. The active treatment groups were comparable to placebo in terms of safety. Conclusions: A specific vitamin B complex (with and without folic acid) significantly improved symptoms of alcoholic polyneuropathy over a 12-week treatment period.
引用
收藏
页码:636 / 642
页数:7
相关论文
共 25 条
[1]   Gender and peripheral neuropathy in chronic alcoholism: A clinical-electroneurographic study [J].
Ammendola, A ;
Gemini, D ;
Iannaccone, S ;
Argenzio, F ;
Ciccone, G ;
Ammendola, E ;
Serio, L ;
Ugolini, G ;
Bravaccio, F .
ALCOHOL AND ALCOHOLISM, 2000, 35 (04) :368-371
[2]   Peripheral neuropathy in chronic alcoholism: A retrospective cross-sectional study in 76 subjects [J].
Ammendola, A ;
Tata, MR ;
Aurilio, C ;
Ciccone, G ;
Gemini, D ;
Ammendola, E ;
Ugolini, G ;
Argenzio, F .
ALCOHOL AND ALCOHOLISM, 2001, 36 (03) :271-275
[3]  
Anisimova E I, 2001, Zh Nevrol Psikhiatr Im S S Korsakova, V101, P32
[4]   Vitamins for chronic disease prevention in adults - Scientific review [J].
Fairfield, KM ;
Fletcher, RH .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2002, 287 (23) :3116-3126
[5]   VITAMIN-B12 AND FOLATE FUNCTION IN CHRONIC-ALCOHOLIC MEN WITH PERIPHERAL NEUROPATHY AND ENCEPHALOPATHY [J].
GIMSING, P ;
MELGAARD, B ;
ANDERSEN, K ;
VILSTRUP, H ;
HIPPE, E .
JOURNAL OF NUTRITION, 1989, 119 (03) :416-424
[6]  
Gloria L, 1997, AM J GASTROENTEROL, V92, P485
[7]  
Haupt E, 2005, INT J CLIN PHARM TH, V43, P71
[8]  
HELL D, 1976, SCHWEIZ MED WSCHR, V106, P1466
[9]  
KIM CI, 1985, DRUG NUTR INTERACT, V3, P99
[10]  
Kräutler B, 2005, BIOCHEM SOC T, V33, P806